November 9 – 15, 2026

A Note From the Editor

It’s been a very busy week for the field, particularly in the U.S.

On Monday, Compass Pathways announced that it had completed the submission of its new drug application to FDA, which seeks approval for its COMP360 psilocybin in treatment-resistant depression.

Three psychedelic applications are now before FDA, with decisions expected in the coming months. While we expect FDA’s review to be considerably accelerated versus conventional cycles, the apparent shelving of the Commissioner’s National Priority Voucher pilot program (as reported by Reuters on Thursday), which aimed to bring reviews down to just one or two months, does raise some questions over timing. Both Compass and Usona Institute, a nonprofit psilocybin developer, are in receipt of those vouchers. We expect FDA will endeavour to honour them, but it is not yet clear precisely how things will proceed.

On Thursday, U.S. Department of Health and Human Services Secretary RFK Jr. hosted a press conference at which the government announced funding for ibogaine development as well as the launch of a $20M funding opportunity to create a psychedelics real-world evidence network, administered by the National Institute of Mental Health.

The biggest surprise of the press conference was that the government has tapped billionaire Mark Cuban’s Cost Plus Drug Company to develop and manufacture ibogaine hydrochloride in the U.S. for use in a PTSD development program. The government, via ARPA-H, has also acquired a dataset from Beond, which operates ibogaine clinics in Mexico.

ARPA-H is committing up to $4.9 million over an initial five years to the effort, though HHS didn’t say how that will be split between awardees. Given that Cuban’s company has little experience with a drug like ibogaine, or in drug development more generally, it’s likely that other partners will be brought in. We understand that at least one Canadian firm is likely to be drafted in to produce the ibogaine itself, at least to start with.

Elsewhere, Delix Therapeutics announced the closing of a $100M Series C on Monday, co-led by Johnson & Johnson’s venture arm, JJDC, and SV Health Investors’ Dementia Discovery Fund. It’s a boost for the company but also for the neuroplastogen field more broadly. We first reported the round and J&J’s participation back in August.

Lastly, the American Psychological Association is hosting a petition for its members and fellows to gauge interest in the formation of a new Division of Psychedelic Science and Practice.

Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelic business, policy, research and beyond.

Josh Hardman
Founder & Editor

November 2 – 8, 2026

A Note From the Editor

It’s been a busy week, with two psilocybin packages now well on their way to an FDA decision.

On Monday, we reported that Usona Institute has filed its new drug application (NDA) for psilocybin in major depressive disorder (MDD), according to sources familiar with the matter. The next morning, Compass Pathways told investors that its NDA, for psilocybin in treatment-resistant depression (TRD), will be filed within two weeks.

Both companies hold Commissioner’s National Priority Vouchers, which aim to shorten review times to just one or two months. Add in Resilient Pharmaceuticals’ refiled MDMA package, and FDA could hand down as many as three psychedelic decisions over the next few months.

It was a busy week beyond the psychedelics field, too, with the news cycle dominated by the U.S. midterm elections, in which Democrats won control of both the House and Senate. In our latest Bulletin, we look at what that shift in power and politics might mean for psychedelics.

Elsewhere in the Bulletin: FDA has responded to a letter that 32 House lawmakers sent it in May; a judge has set a September 2027 trial date in Terran Biosciences’ trade secrets suit against Compass; we look at what ICER’s 2019 review of Spravato might tell us about its review of Compass’ psilocybin; and much, much more.

If you’re more of a listener than a reader, Episode 4 of The Psychedelic News Feed Podcast was published on Monday.

Two quick reminders: ICER’s comment period on its draft scoping document for Compass’ psilocybin closes this Tuesday, November 10th, and FDA’s ibogaine request for information closes on November 20th.

Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelic business, policy, research and beyond.

Josh Hardman
Founder & Editor

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
The Psychedelic News Feed Podcast
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers
Exclusive audio dispatches from our Editor

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.